Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Semler Scientific, Inc. (OTC: SMLR).

Full DD Report for SMLR

You must become a subscriber to view this report.


Recent News from (OTC: SMLR)

Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q2 2018 Results - Earnings Call Transcript
Semler Scientific, Inc. (SMLR) Q2 2018 Results Earnings Conference Call July 31, 2018 11:00 AM ET Executives Doug Murphy-Chutorian - CEO Analysts Brooks O'Neil - Lake Street Capital Brian Marckx - Zacks Investment Research Presentation Operator Good day, ladies and ...
Source: SeekingAlpha
Date: July, 31 2018 22:24
Semler Scientific reports Q2 results
Semler Scientific ( OTC:SMLR ): Q2 EPS of $0.19 More news on: Semler Scientific Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: July, 31 2018 08:05
Semler Reports Second Quarter and First Half 2018 Financial Results
SAN JOSE, Calif. , July 31, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and...
Source: PR Newswire
Date: July, 31 2018 08:03
Semler to Report Second Quarter and First Half 2018 Financial Results and Host Conference Call on July 31, 2018
SAN JOSE, Calif. , July 23, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report second ...
Source: PR Newswire
Date: July, 23 2018 08:03
By The Numbers: Growth Leaders With Rising Earnings Expectations
Growth investing is a widely popular strategy, and for valid reasons. At the end of the day a stock is simply a share in an ownership of a business, and businesses with superior growth rates tend to generate more value for investors over time. The following paragraphs will be introducing a q...
Source: SeekingAlpha
Date: July, 09 2018 09:57
Semler Scientific's (SMLR) CEO Dr. Doug Murphy-Chutorian on Q1 2018 Results - Earnings Call Transcript
Semler Scientific, Inc. (SMLR) Q1 2018 Results Earnings Conference Call May 01, 2018 11:00 AM ET Executives Dr. Doug Murphy-Chutorian - CEO Analysts Brian Marckx - Zacks Investment Research David Lavigne - Trickle Research Presentation Operator Good day, ladies and ...
Source: SeekingAlpha
Date: May, 01 2018 15:29
Semler Reports First Quarter 2018 Financial Results
SAN JOSE, Calif. , May 1, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months ende...
Source: PR Newswire
Date: May, 01 2018 08:03
Semler to Report First Quarter 2018 Financial Results and Host Conference Call on May 1, 2018
SAN JOSE, Calif. , April 19, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report first ...
Source: PR Newswire
Date: April, 19 2018 08:03
New Research Reports on Semler Scientific and Americas United Bank - Emerging Growth Amid 2018's Outlook
NEW YORK, NY / ACCESSWIRE / March 5 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Semler Scientific Inc. ( OTCQB: SMLR) and Americas United Bank (OTC PINK: AUNB), including recent technical analysis and consolidated fundamental informat...
Source: ACCESSWIRE IA
Date: March, 05 2018 07:30
Semler Scientific's (SMLR) CEO Douglas Murphy-Chutorian on Q4 2017 Results - Earnings Call Transcript
Semler Scientific, Inc. (SMLR) Q4 2017 Earnings Conference Call February 28, 2018 11:00 AM ET Executives Douglas Murphy-Chutorian - Chief Executive Officer Analysts Brian Marckx - Zacks Investment Research David Lavigne - Trickle Research LLC John Henderson - Kershner Tradi...
Source: SeekingAlpha
Date: February, 28 2018 14:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1429.7531.0031.0029.758,570
2018-12-1331.2030.1931.2028.5321,130
2018-12-1231.12531.0031.9031.0044,202
2018-12-1132.0031.2532.5031.0045,890
2018-12-1030.6032.5033.0030.5912,815

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143,2108,57037.4562Short
2018-12-133,36121,13015.9063Cover
2018-12-1218,60244,20242.0841Short
2018-12-1115,14945,89033.0115Cover
2018-12-106,21012,81548.4588Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SMLR.


About Semler Scientific, Inc. (OTC: SMLR)

Logo for Semler Scientific, Inc. (OTC: SMLR)

Semler Scientific, Inc. is an emerging medical risk assessment company. Its mission is to develop, manufacture and market patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases. Semler s first patented and U.S. Food and Drug Administration cleared product, is FloChec. FloChec is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. Additional information about Semler can be found at www.semlerscientific.com.

 

 

 

Current Management

  • Douglas MurphyChutorian / CEO
    • Dr. Douglas MurphyChutorian has served as a member of our Board of Directors since September and as our Chief Executive Officer since October , . Dr. MurphyChutorian has had broad, diverse career experience in healthcare over the past years, stretching from clinician, academician, inventor, entrepreneur, Chief Executive Officer, Chairman of the Board, and consultant to financial firms. Since April , , he has been Managing Director of Select Healthcare Capital, LLC. Dr. MurphyChutorian is a named inventor on more than patents, and has guided more than products through various regulatory approval processes. His business career has included extensive involvement in all facets of the medical industry from financial, research and development, manufacturing, marketing and sales, regulatory, reimbursement, and clinical trials. His breadth of healthcare experience includes all major sectors of the industry: medical devices, health services, pharmaceuticals, biotechnology and managed care. He received his B.A. and M.D. from Columbia University. He completed his Internal Medicine residency at New York University/Bellevue Medical Center and his fellowship in Cardiology at Stanford University Medical Center. He has served as a faculty member in interventional cardiology at both Stanford and Montefiore Medical Center. Dr. MurphyChutorian s experience as a cardiologist, inventor and executive qualify him to be our Director and Chief Executive Officer.
  • Daniel E. Conger / VP, Fin. amp Acct.
    • Mr. Daniel E. Conger has served as our Vice President of Finance since October . From September until joining our company, Mr. Conger worked at Bacchus Vascular and its acquirer Covidien, Inc., a medical device, supplies and pharmaceuticals company, where he was the Plant Controller for the San Jose plant. At Covidien, Mr. Conger was responsible for creation of a million annual budget, leading a team of six people. He had sole responsibility for preparation of monthly and quarterly financial statements, and presented quarterly results to executive management of the global business unit. Mr. Conger has been working in the medical device, startup and biotechnology industries since , and has experience designing internal control systems, implementing such systems, and running finance in a business centered manner. He received his B.S. in Business Administration from Humboldt State University in May and an MBA Accounting Option from California State University East Bay in June .
  • Arthur N. Leibowitz /
  • Wayne T. Pan /

Current Share Structure

  • Market Cap: $52,858,132 - 03/09/2018
  • Authorized: 50,000,000 - 03/09/2018
  • Issue and Outstanding: 5,939,116 - 03/09/2018
  • Float: 2,700,876 - 07/20/2017

 


Recent Filings from (OTC: SMLR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 24 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 03 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 31 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 04 2017
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: September, 15 2017

 

 


Daily Technical Chart for (OTC: SMLR)

Daily Technical Chart for (OTC: SMLR)


Stay tuned for daily updates and more on (OTC: SMLR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SMLR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SMLR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SMLR and does not buy, sell, or trade any shares of SMLR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/